On June 21, Gelunhui reported that Hubei Biocause Pharmaceutical (000627.SZ) stated on the investor interaction platform that China Best Life Insurance maintains a moderate business scale and continues to promote the optimization of business structure, asset allocation structure, and steady promotion of asset-liability matching according to the established development strategy. It continuously strengthens the application of new technologies and talent reserve, improves the company's operational management system, and comprehensively enhances the company's operational capabilities. While ensuring the basic stability of premium income, according to market conditions, it timely adjusts the business rhythm and structure, vigorously promotes the development of long-term value and risk protection-oriented business. At present, the operation of China Best Life Insurance is in order, with accumulated original insurance premium income of about RMB 20.6 billion from January 1, 2024 to May 31, 2024, overall moderate and stable scale.